Drug profile

The FDA adverse-event record for Glucosamine Hydrochloride/Sodium Chondroitin Sulfate/Manganese

21 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Hydrochloride/Sodium Chondroitin Sulfate/Manganese. See the species affected, top reactions, and outcomes below.

21
adverse-event reports
9.5%
death-coded share
Dog
most-reported species
5
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
2
Deaths Reported
9.5%
Death Rate

Active Ingredients

Glucosamine Hydrochloride/Sodium Chondroitin Sulfate/Manganese

Administration Routes

OralUnknown

Species Affected

Dog 17
Cat 4

Most Affected Breeds

Retriever - Labrador 3
Domestic Shorthair 3
Pit Bull 2
Siamese 1
Boxer (German Boxer) 1
Terrier - West Highland White 1
Great Pyrenees 1
Bulldog - American 1
Retriever - Golden 1
Siberian Husky 1

Most Reported Reactions

Lack of efficacy - NOS 5
Behavioural disorder NOS 4
Diarrhoea 3
Vomiting 3
Anorexia 2
Death by euthanasia 2
Mass NOS 2
Hyperactivity 2
Hallucination 2
Hypertension 2
Renal disorder NOS 2
Urinary retention 2

Outcome Breakdown

Outcome Unknown
14 (66.7%)
Recovered/Normal
3 (14.3%)
Ongoing
2 (9.5%)
Euthanized
2 (9.5%)

Glucosamine Hydrochloride/Sodium Chondroitin Sulfate/Manganese Adverse Event Insights

21 reports name Glucosamine Hydrochloride/Sodium Chondroitin Sulfate/Manganese; 2 recorded a death outcome (9.5% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Hydrochloride/Sodium Chondroitin Sulfate/Manganese. Administration routes: Oral, Unknown.

By species: Dog (17 reports), Cat (4 reports). By breed: Retriever - Labrador (3), Domestic Shorthair (3), Pit Bull (2).

Leading clinical signs: Lack of efficacy - NOS (5), Behavioural disorder NOS (4), Diarrhoea (3), Vomiting (3). Outcome, 21 coded reports: Outcome Unknown leads at 66.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.